Advertisement
Advertisement
Werewolf Therapeutics receives FTD from U.S. FDA for WTX-124
PremiumThe FlyWerewolf Therapeutics receives FTD from U.S. FDA for WTX-124
1M ago
Werewolf Therapeutics Faces Nasdaq Compliance Challenge
Premium
Company Announcements
Werewolf Therapeutics Faces Nasdaq Compliance Challenge
1M ago
Werewolf Therapeutics price target lowered to $8 from $9 at BofA
Premium
The Fly
Werewolf Therapeutics price target lowered to $8 from $9 at BofA
3M ago
Werewolf Therapeutics Reports Q2 2025 Financial Results
PremiumCompany AnnouncementsWerewolf Therapeutics Reports Q2 2025 Financial Results
3M ago
Werewolf Therapeutics sees cash runway into 4Q26
Premium
The Fly
Werewolf Therapeutics sees cash runway into 4Q26
3M ago
Werewolf Therapeutics reports Q2 EPS (40c), consensus (37c)
Premium
The Fly
Werewolf Therapeutics reports Q2 EPS (40c), consensus (37c)
3M ago
Werewolf Therapeutics price target lowered to $6 from $8 at Wedbush
PremiumThe FlyWerewolf Therapeutics price target lowered to $6 from $8 at Wedbush
6M ago
Werewolf Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Werewolf Therapeutics Reports Q1 2025 Financial Results
6M ago
Werewolf Therapeutics files $150M mixed securities shelf
Premium
The Fly
Werewolf Therapeutics files $150M mixed securities shelf
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100